Andrew C. Von Eschenbach

Insider · Director · BLCO

Andrew C. Von Eschenbach files insider transactions with the SEC as a director of Bausch & Lomb (BLCO). We hold 3 disclosed purchases and sales filed since 3 July 2012, 2 of them in the last 90 days.

Files forBLCO
Disclosed buys and sells3 in all, 2 in the last 90 days
Last disclosure10 August 2026

Positions held

7 posts we hold — a term names its own dates; a run of filings only says when they filed

Filed 10 May 2022 — 7 August 2026Director · Bausch & Lomb (BLCO)12 Form 4 lines · source: SEC Form 4
Filed 10 August 2023 — 13 August 2024Director · TriSalus Life Sciences (TLSI)4 Form 4 lines · source: SEC Form 4
Filed 16 July 2021 — 14 June 2023Director · Celularity (CELU)9 Form 4 lines · source: SEC Form 4
Filed 4 January 2021 — 15 August 2022Director · Radius Health (RDUS)5 Form 4 lines · source: SEC Form 4
Filed 29 October 2018 — 5 August 2021Director · Bausch Health Companies (BHC)6 Form 4 lines · source: SEC Form 4
Filed 1 April 2014 — 1 April 2014Director · Asterias Biotherapeutics (NONE)1 Form 4 line · source: SEC Form 4
Filed 1 July 2012 — 12 August 2013Director · Biotime (BTX)3 Form 4 lines · source: SEC Form 4

Everything they disclosed

40 entries, newest first — one per disclosure report, one per Form 4 line

▼ sold on the open market 12,500 shares of Bausch & LombSEC Form 410 August 2026Common Shares, No Par Value · traded 6 August 2026 · filed 10 August 2026
▼ sold on the open market 6,059 shares of Bausch & LombSEC Form 410 August 2026Common Shares, No Par Value · traded 7 August 2026 · filed 10 August 2026
was granted 15,842 shares of Bausch & LombSEC Form 428 May 2026Common Shares, No Par Value · traded 26 May 2026 · filed 28 May 2026
▲ bought on the open market 4,364 shares of Bausch & LombSEC Form 43 March 2026Common Shares, No Par Value · traded 27 February 2026 · filed 3 March 2026
was granted 4,364 shares of Bausch & LombSEC Form 43 March 2026Common Shares, No Par Value · traded 27 February 2026 · filed 3 March 2026
▲ bought on the open market 4,364 shares of Bausch & LombSEC Form 43 March 2026Common Shares, No Par Value · traded 27 February 2026 · filed 3 March 2026
was granted 4,364 shares of Bausch & LombSEC Form 43 March 2026Common Shares, No Par Value · traded 27 February 2026 · filed 3 March 2026
was granted 20,338 shares of Bausch & LombSEC Form 428 May 2025Common Shares, No Par Value · traded 27 May 2025 · filed 28 May 2025
▲ bought on the open market 1,695 shares of Bausch & LombSEC Form 46 May 2025Common Shares, No Par Value · traded 2 May 2025 · filed 6 May 2025
was granted 15,000 shares of TriSalus Life Sciences (a derivative holding)SEC Form 421 August 2024Director stock option (right to buy) · traded 13 August 2024 · filed 21 August 2024
was granted 14,696 shares of Bausch & LombSEC Form 46 August 2024Common Shares, No Par Value · traded 2 August 2024 · filed 6 August 2024
gave away 35,000 shares of TriSalus Life Sciences (a derivative holding)SEC Form 45 June 2024Stock Option (right to buy) · traded 3 June 2024 · filed 5 June 2024
gave away 35,000 shares of TriSalus Life Sciences (a derivative holding)SEC Form 45 June 2024Stock Option (right to buy) · traded 3 June 2024 · filed 5 June 2024
was granted 35,000 shares of TriSalus Life Sciences (a derivative holding)SEC Form 414 August 2023Stock Option (right to buy) · traded 10 August 2023 · filed 14 August 2023
was granted 277,778 shares of Celularity (a derivative holding)SEC Form 416 June 2023Stock Option (Right to Buy) · traded 14 June 2023 · filed 16 June 2023
was granted 199,921 shares of CelularitySEC Form 416 June 2023Class A Common Stock · traded 14 June 2023 · filed 16 June 2023
was granted 12,857 shares of Bausch & LombSEC Form 45 May 2023Common Shares, No Par Value · traded 4 May 2023 · filed 5 May 2023
returned to the issuer 10,000 shares of Radius Health (a derivative holding)SEC Form 415 August 2022Stock Option (Right to Buy) · traded 15 August 2022 · filed 15 August 2022
returned to the issuer 5,500 shares of Radius HealthSEC Form 415 August 2022Common Stock · traded 15 August 2022 · filed 15 August 2022
was granted 54,152 shares of Celularity (a derivative holding)SEC Form 415 July 2022Stock Option (Right to Buy) · traded 13 July 2022 · filed 15 July 2022
was granted 36,145 shares of CelularitySEC Form 415 July 2022Class A Common Stock · traded 13 July 2022 · filed 15 July 2022
was granted 12,500 shares of Bausch & LombSEC Form 412 May 2022Common Shares, No Par Value · traded 10 May 2022 · filed 12 May 2022
was granted 10,000 shares of Radius Health (a derivative holding)SEC Form 425 January 2022Stock Option (Right to Buy) · traded 14 January 2022 · filed 25 January 2022
was granted 5,500 shares of Radius HealthSEC Form 425 January 2022Common Stock · traded 14 January 2022 · filed 25 January 2022
exercised options over 100,000 shares of Celularity (a derivative holding)SEC Form 42 December 2021Stock Option (Right to Buy) · traded 9 November 2021 · filed 2 December 2021
exercised options over 100,000 shares of CelularitySEC Form 42 December 2021Class A Common Stock · traded 9 November 2021 · filed 2 December 2021
was granted 56,053 shares of Celularity (a derivative holding)SEC Form 413 September 2021Stock Option (Right to Buy) · traded 9 September 2021 · filed 13 September 2021
▲ bought on the open market 1,400 shares of Bausch Health CompaniesSEC Form 49 August 2021Common Shares, No Par Value · traded 5 August 2021 · filed 9 August 2021
was granted 307,437 shares of Celularity (a derivative holding)SEC Form 420 July 2021Stock Option (Right to Buy) · traded 16 July 2021 · filed 20 July 2021
was granted 269,007 shares of Celularity (a derivative holding)SEC Form 420 July 2021Deferred Compensation Award (Right to Buy) · traded 16 July 2021 · filed 20 July 2021
was granted 7,645 shares of Bausch Health CompaniesSEC Form 43 May 2021Common Shares, No Par Value · traded 30 April 2021 · filed 3 May 2021
was granted 30,000 shares of Radius Health (a derivative holding)SEC Form 45 January 2021Stock Option (Right to Buy) · traded 4 January 2021 · filed 5 January 2021
was granted 11,037 shares of Bausch Health CompaniesSEC Form 41 May 2020Common Shares, No Par Value · traded 1 May 2020 · filed 1 May 2020
▲ bought on the open market 1,100 shares of Bausch Health CompaniesSEC Form 411 March 2020Common Shares, No Par Value · traded 10 March 2020 · filed 11 March 2020
was granted 10,633 shares of Bausch Health CompaniesSEC Form 43 May 2019Common Shares, No Par Value · traded 3 May 2019 · filed 3 May 2019
was granted 5,832 shares of Bausch Health CompaniesSEC Form 431 October 2018Common Shares, No Par Value · traded 29 October 2018 · filed 31 October 2018
acquired or disposed of, other 20,000 shares of Asterias Biotherapeutics (a derivative holding)SEC Form 43 April 2014Option to Purchase Series B Common Stock · traded 1 April 2014 · filed 3 April 2014
▲ bought on the open market 3,000 shares of BiotimeSEC Form 414 August 2013Common Shares, no par value · traded 12 August 2013 · filed 14 August 2013
was granted 20,000 shares of Biotime (a derivative holding)SEC Form 45 July 2013Option to Purchase Common Shares · traded 1 July 2013 · filed 5 July 2013
was granted 20,000 shares of Biotime (a derivative holding)SEC Form 43 July 2012Option to Purchase Common Shares · traded 1 July 2012 · filed 3 July 2012

Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.